US biotech firm Novavax on Monday said it had delayed plans to seek authorization for its Covid vaccine candidate, a setback for developing countries hoping the injection would soon be available.

The company now hopes to file for authorization in the US and Europe in the third quarter of 2021, it said in a statement, sending shares tumbling 12 percent.

Novavax's vaccine is key to the Covax program, which was set up to try to ensure poor countries have equitable access to vaccines to combat the coronavirus pandemic.

Its NVX-CoV2373 vaccine candidate demonstrated 100 percent protection against severe disease in a Phase 3 clinical trial in Britain, with 89.7 percent efficacy against any form of the disease.

It uses a piece of the SARS-CoV-2 virus called the spike protein, which the company mass-produces inside insect cells, and can be stored at regular refrigeration temperatures.

Novavax also said Monday it had had positive results from preclinical studies of a shot combining its influenza and Covid vaccine candidates.

The company said a study, which will now undergo peer review, showed that the shot produced strong levels of antibodies against both diseases in ferrets and hamsters.

"Despite low rates during the Covid-19 pandemic, influenza remains a significant risk to global public health and the need for versatile, more effective vaccines is as important as ever, including against the flu," said Gregory Glenn, the company's president of R&D.

The new vaccine combines NanoFlu and NVX-CoV2373.

Hamsters that were vaccinated and then deliberately infected with the coronavirus retained their body weight compared to those that received a placebo.

Lung samples taken from the immunized animals after they were put down showed they were Covid-free.

Novavax developing combination flu, Covid vaccine
Washington (AFP) May 10, 2021 - US biotech firm Novavax on Monday said it had positive results from preclinical studies of a shot combining its influenza and Covid vaccine candidates.

The company said a study, which it has posted to a preprint server and will now undergo peer review, showed that the shot produced strong levels of antibodies against both diseases in ferrets and hamsters.

"Despite low rates during the Covid-19 pandemic, influenza remains a significant risk to global public health and the need for versatile, more effective vaccines is as important as ever, including against the flu," said Gregory Glenn, the company's president of R&D.

The new vaccine combines NanoFlu and NVX-CoV2373, which are separately in late-stage human trials. Neither have yet been approved.

Hamsters that were vaccinated and then deliberately infected with the coronavirus retained their body weight compared to those that received a placebo.

Lung samples taken from the immunized animals after they were put down showed they were Covid-free.

NVX-CoV2373, the company's Covid vaccine candidate, demonstrated 100 percent protection against severe disease in a Phase 3 clinical trial in the United Kingdom, with 89.7 percent efficacy against any form of disease.

NVX-CoV2373 uses a piece of the SARS-CoV-2 virus called the spike protein, which the company mass produces inside insect cells.

It packages the spike inside nanoparticles and delivers these to the immune system, which trains the host in case they encounter the real virus.

The vaccine contains a substance called an adjuvant to deliver a stronger signal to the immune system to respond.

NanoFlu is based on similar principles but instead of the spike protein, it presents hemagglutinin -- a protein on the outside of the influenza virus -- to the immune system.

Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola

Tweet

Thanks for being here; We need your help. The Space Media Network continues to grow but revenues have never been harder to maintain. With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceMediaNetwork Contributor $5 Billed Once credit card or paypal		SpaceMediaNetwork Monthly Supporter $5 Billed Monthly paypal only

Dust storms and valley fever in the American West
Greenbelt MD (SPX) May 07, 2021
Valley fever is a dangerous threat to human health - and cases are on the rise in the arid southwestern United States, as wind from increasing dust storms can transport the fungal spores that cause the disease. Valley fever is caused by the Coccidioides fungus, which grows in dirt and fields and can cause fever, rash and coughing. Using NASA research and satellite data, the World Meteorological Organization is refining its Sand and Dust Storm Warning Advisory and Assessment System to help forecast where ... read more